Cat. No. 5701
Chemical Name: 5-Chloro-4-[2-[[(2-chloro-4-cyclopr
Biological ActivityPotent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonist (IC50 values are 8 and 35 nM, respectively in plasma). Inhibits PGD2-induced down modulation of CRTH2 on CD16- granulocytes in human whole blood as well as PGD2-induced cAMP response in platelets. Inhibits PGD2-induced airway constriction in vivo. Also inhibits BRD4 (Kd = 170 nM). Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Liu et al (2011) Discovery of AMG 853, a CRTH2 and DP dual antagonist. ACS Med.Chem.Lett. 2 326. PMID: 24900313.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AMG 853 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: AMG 853, supplier, AMG853, CRTH2, chemoattractant, receptor-homologous, molecule, expressed, on, Th2, cells, PGD2, prostaglandin, receptor, dual, antagonists, antagonism, orally, bioavailable, Tocris Bioscience, Prostanoid Receptor Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonist
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.